Literature DB >> 32064528

Absence of MeCP2 binding to non-methylated GT-rich sequences in vivo.

John C Connelly1, Justyna Cholewa-Waclaw1, Shaun Webb1, Verdiana Steccanella1, Bartlomiej Waclaw2, Adrian Bird1.   

Abstract

MeCP2 is a nuclear protein that binds to sites of cytosine methylation in the genome. While most evidence confirms this epigenetic mark as the primary determinant of DNA binding, MeCP2 is also reported to have an affinity for non-methylated DNA sequences. Here we investigated the molecular basis and in vivo significance of its reported affinity for non-methylated GT-rich sequences. We confirmed this interaction with isolated domains of MeCP2 in vitro and defined a minimal target DNA sequence. Binding depends on pyrimidine 5' methyl groups provided by thymine and requires adjacent guanines and a correctly orientated A/T-rich flanking sequence. Unexpectedly, full-length MeCP2 protein failed to bind GT-rich sequences in vitro. To test for MeCP2 binding to these motifs in vivo, we analysed human neuronal cells using ChIP-seq and ATAC-seq technologies. While both methods robustly detected DNA methylation-dependent binding of MeCP2 to mCG and mCAC, neither showed evidence of MeCP2 binding to GT-rich motifs. The data suggest that GT binding is an in vitro phenomenon without in vivo relevance. Our findings argue that MeCP2 does not read unadorned DNA sequence and therefore support the notion that its primary role is to interpret epigenetic modifications of DNA.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32064528      PMCID: PMC7144902          DOI: 10.1093/nar/gkaa102

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  33 in total

1.  Chicken MAR-binding protein ARBP is homologous to rat methyl-CpG-binding protein MeCP2.

Authors:  J M Weitzel; H Buhrmester; W H Strätling
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG.

Authors:  Robert J Klose; Shireen A Sarraf; Lars Schmiedeberg; Suzanne M McDermott; Irina Stancheva; Adrian P Bird
Journal:  Mol Cell       Date:  2005-09-02       Impact factor: 17.970

3.  5-hydroxymethylcytosine accumulation in postmitotic neurons results in functional demethylation of expressed genes.

Authors:  Marian Mellén; Pinar Ayata; Nathaniel Heintz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

4.  Plasticity at the DNA recognition site of the MeCP2 mCG-binding domain.

Authors:  Ming Lei; Wolfram Tempel; Sizhuo Chen; Ke Liu; Jinrong Min
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-26       Impact factor: 4.490

5.  DNA methylation in the gene body influences MeCP2-mediated gene repression.

Authors:  Benyam Kinde; Dennis Y Wu; Michael E Greenberg; Harrison W Gabel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-13       Impact factor: 11.205

6.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).

Authors:  Victoria Valinluck; Hsin-Hao Tsai; Daniel K Rogstad; Artur Burdzy; Adrian Bird; Lawrence C Sowers
Journal:  Nucleic Acids Res       Date:  2004-08-09       Impact factor: 16.971

7.  MeCP2 Binding Cooperativity Inhibits DNA Modification-Specific Recognition.

Authors:  Sergei Khrapunov; Yisong Tao; Huiyong Cheng; Camille Padlan; Richard Harris; Aristea S Galanopoulou; John M Greally; Mark E Girvin; Michael Brenowitz
Journal:  Biochemistry       Date:  2016-07-28       Impact factor: 3.162

8.  Dynamic DNA methylation across diverse human cell lines and tissues.

Authors:  Katherine E Varley; Jason Gertz; Kevin M Bowling; Stephanie L Parker; Timothy E Reddy; Florencia Pauli-Behn; Marie K Cross; Brian A Williams; John A Stamatoyannopoulos; Gregory E Crawford; Devin M Absher; Barbara J Wold; Richard M Myers
Journal:  Genome Res       Date:  2013-01-16       Impact factor: 9.043

9.  An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders.

Authors:  Steven Andrew Baker; Lin Chen; Angela Dawn Wilkins; Peng Yu; Olivier Lichtarge; Huda Yahya Zoghbi
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

10.  Sequence-specific DNA binding by AT-hook motifs in MeCP2.

Authors:  Matthew J Lyst; John Connelly; Cara Merusi; Adrian Bird
Journal:  FEBS Lett       Date:  2016-08-09       Impact factor: 4.124

View more
  5 in total

Review 1.  Emerging Insights into the Distinctive Neuronal Methylome.

Authors:  Adam W Clemens; Harrison W Gabel
Journal:  Trends Genet       Date:  2020-08-21       Impact factor: 11.639

2.  Neuronal non-CG methylation is an essential target for MeCP2 function.

Authors:  Rebekah Tillotson; Justyna Cholewa-Waclaw; Kashyap Chhatbar; John C Connelly; Sophie A Kirschner; Shaun Webb; Martha V Koerner; Jim Selfridge; David A Kelly; Dina De Sousa; Kyla Brown; Matthew J Lyst; Skirmantas Kriaucionis; Adrian Bird
Journal:  Mol Cell       Date:  2021-02-08       Impact factor: 17.970

Review 3.  The Molecular Functions of MeCP2 in Rett Syndrome Pathology.

Authors:  Osman Sharifi; Dag H Yasui
Journal:  Front Genet       Date:  2021-04-23       Impact factor: 4.599

4.  Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells.

Authors:  Karolina Łuczkowska; Olga Taryma-Leśniak; Jan Bińkowski; Katarzyna E Sokołowska; Dominik Strapagiel; Justyna Jarczak; Edyta Paczkowska; Bogusław Machaliński; Tomasz K Wojdacz
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

5.  A critique of the hypothesis that CA repeats are primary targets of neuronal MeCP2.

Authors:  Kashyap Chhatbar; John Connelly; Shaun Webb; Skirmantas Kriaucionis; Adrian Bird
Journal:  Life Sci Alliance       Date:  2022-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.